<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906137</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS EP61 GALT</org_study_id>
    <nct_id>NCT02906137</nct_id>
  </id_info>
  <brief_title>Gut-Associated Lymphocyte Trafficking</brief_title>
  <acronym>GALT</acronym>
  <official_title>Altered Homing of T Lymphocytes to the Gut and Poor Immune Reconstitution of the Intestinal Mucosa in Treated HIV-infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gut immune barrier is not fully restored in HIV-1-infected subjects despite they were&#xD;
      receiving antiretroviral treatment. This leaky gut leads to microbial translocation from the&#xD;
      gut lumen into the bloodstream that fuels deleterious systemic inflammation. The chemotaxis&#xD;
      axes that allow T lymphocytes to migrate from the blood to the gut mucosa in order to&#xD;
      reconstitute the mucosal immune barrier seems altered in treated HIV-1-infected subjects.This&#xD;
      study aims at better understanding the mechanisms involved in this lack of mucosal immune&#xD;
      restoration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pathophysiological study in human subjects, comparative, national, multicentric and&#xD;
      prospective. Peripheral blood and intestinal biopsies will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune status: Measure of the frequencies of Th1 in peripheral blood and gut mucosa.</measure>
    <time_frame>Baseline</time_frame>
    <description>The frequencies of Th1 will be measured by flow cytometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune status: Measure of the frequencies of Th17 in peripheral blood and gut mucosa.</measure>
    <time_frame>Baseline</time_frame>
    <description>The frequencies of Th17 will be measured by flow cytometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune status: Measure of the frequencies of Th22 in peripheral blood and gut mucosa.</measure>
    <time_frame>Baseline</time_frame>
    <description>The frequencies of Th22 will be measured by flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune status: Quantification of cytokines in blood and gut mucosa.</measure>
    <time_frame>Baseline</time_frame>
    <description>The quantification of cytokines will be measured by luminex.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune status: Quantification of cytokines in blood and gut mucosa.</measure>
    <time_frame>Baseline</time_frame>
    <description>The quantification of cytokines will be measured by immuno-histochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune status: Quantification of chemiokines in blood and gut mucosa.</measure>
    <time_frame>Baseline</time_frame>
    <description>The quantification of chemiokines will be measured by luminex.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune status: Quantification of chemiokines in blood and gut mucosa.</measure>
    <time_frame>Baseline</time_frame>
    <description>The quantification of chemiokines will be measured by immuno-histochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial translocation : Quantification of soluble CD14 in plasma.</measure>
    <time_frame>Baseline</time_frame>
    <description>The quantification of CD 14 will be realised by Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial translocation : Quantification of soluble soluble CD163 in plasma.</measure>
    <time_frame>Baseline</time_frame>
    <description>The quantification of CD163 will be realised by Enzyme-Linked Immunosorbent Assay (ELISA) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial translocation : Quantification of Lipopolysaccharide Binding Protein (LBP).</measure>
    <time_frame>Baseline</time_frame>
    <description>The quantification of Lipopolysaccharide Binding Protein will be realised by Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial translocation : Quantification of Intestinal-type Fatty Acid-Binding Protein (I-FABP) in plasma.</measure>
    <time_frame>Baseline</time_frame>
    <description>The quantification of Intestinal-type Fatty Acid-Binding Protein (I-FABP) will be realised by Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial translocation : Quantification of 16S RNA.</measure>
    <time_frame>Baseline</time_frame>
    <description>The quantification of 16S RNA will be realised by real-time Polymerase Chaine Reaction (qPCR).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>HIV-1 infected subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 subjects will be recruited in the Department of Infectious Diseases of Toulouse University Hospital, France:&#xD;
15 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling&#xD;
15 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling&#xD;
10 subjects will have both a gastroscopy and a coloscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uninfected-controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 subjects will be recruited in the Department of Internal Medicine of Toulouse University Hospital, France:&#xD;
10 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling&#xD;
10 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling&#xD;
10 subjects will have both a gastroscopy and a coloscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peripheral blood and intestinal biopsies will be collected</intervention_name>
    <description>Blood draw and intestinal biopsies</description>
    <arm_group_label>HIV-1 infected subjects</arm_group_label>
    <arm_group_label>Uninfected-controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria are:&#xD;
&#xD;
        For HIV-1-infected subjects group :&#xD;
&#xD;
          -  Age at least 18-year old&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Receiving continuous cART for ≥ 12 months, started during the chronic phase&#xD;
&#xD;
          -  Plasma viral load ≤50 copies/mL for ≥ 6 months (one blip ≤200 copies/mL authorized)&#xD;
&#xD;
          -  Blood CD4+ T cells count ≥ 350 cells/mm3&#xD;
&#xD;
          -  Indication for upper and/or lower digestive endoscopy&#xD;
&#xD;
          -  Patient enrolled in or a beneficiary of a Social Security programme (State Medical Aid&#xD;
             or AME is not a Social Security programme)&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        For uninfected control group :&#xD;
&#xD;
          -  Age at least 18-year old&#xD;
&#xD;
          -  Indication for upper and/or lower digestive endoscopy&#xD;
&#xD;
          -  Patient enrolled in or a beneficiary of a Social Security programme (State Medical Aid&#xD;
             or AME is not a Social Security programme)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria are:&#xD;
&#xD;
        For HIV-1-infected subject group :&#xD;
&#xD;
          -  HIV-2 infection&#xD;
&#xD;
          -  Inflammatory bowel diseases (Crohn's disease, ulcerative colitis) ; coeliac disease&#xD;
&#xD;
          -  Platelets count &lt;50 G/L or abnormal hemostasis tests&#xD;
&#xD;
          -  Decompensated cirrhosis&#xD;
&#xD;
          -  Past or current lymphoma&#xD;
&#xD;
          -  Involvement in an HIV-1 immunotherapeutic vaccine study&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Subjects participating in a study excluding participating in another study&#xD;
&#xD;
          -  Vulnerability, such as an age under 18, tutorship, trusteeship, or subjects deprived&#xD;
             of liberty by a legal or administrative decision.&#xD;
&#xD;
        For uninfected control group :&#xD;
&#xD;
          -  HIV-1 and 2 infection&#xD;
&#xD;
          -  Inflammatory bowel diseases (Crohn's disease, ulcerative colitis) ; coeliac disease&#xD;
&#xD;
          -  Platelets count &lt;50 G/L or abnormal hemostasis tests&#xD;
&#xD;
          -  Decompensated cirrhosis&#xD;
&#xD;
          -  Past or current lymphoma&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Subjects participating in a study excluding participating in another study&#xD;
&#xD;
          -  Vulnerability, such as an age under 18, tutorship, trusteeship, or subjects deprived&#xD;
             of liberty by a legal or administrative decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Delobel, Dr</last_name>
    <phone>05 61 77 75 08</phone>
    <email>delobel.p@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Purpan - Service de Médecine Interne</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Alric, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan - Service des maladies Infectieuses</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Delobel, Dr</last_name>
      <phone>05 61 77 75 08</phone>
      <email>delobel.p@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

